Oncology On GDF-15 neutralisation and cachexia, with CatalYm As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.
R&D Sponsored Beyond recruitment: Creating patient engagement that lasts In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.
R&D Taking the microbiome seriously, with Sam Possemiers pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.
Oncology Dr Michael Bauer on Quantro’s mission to drug the “undruggab... Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.
R&D Sponsored Turning recruitment potential into enrolment reality In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs
R&D Sponsored Decentralisation by design: Bringing the trial closer withou... In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
